Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 24-year-old shared a 4-month update on their hair transplant of 3900 grafts done by Dr. Serkan Aygin in Turkey, costing 3100 euros. They have been using topical minoxidil at night and 1mg of finasteride daily for about a year and a half before the transplant.

The user has been on finasteride for 7 years and had a hair transplant, but is experiencing hair thinning and itchiness, particularly on one side, leading to concerns about male pattern baldness or other health issues. Despite having a full head of hair, the user is considering shaving it due to mental health struggles and is advised to consult a therapist and consider other treatments like minoxidil or dutasteride.

A user shared their positive experience with scalp micropigmentation (SMP) to cover hair thinning and a scar, choosing it over hair transplants due to its non-invasive nature and realistic results. They recommend SMP for those struggling with hair loss, emphasizing the importance of finding a trusted artist.

A 35-year-old man had a 6400 graft hair transplant in Turkey after years of baldness, using finasteride, oral and topical minoxidil, and scalp micropigmentation. He is satisfied with the progress and plans further SMP touch-ups to enhance results.

A 24-year-old woman with AGA and TE since age 14 is questioning if her hair is regrowing or breaking. She has been using minoxidil consistently since September 2025, along with caffeine and ketoconazole shampoos, rosemary oil, and saw palmetto, and has improved her overall hair care routine.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

A 35-year-old man underwent a 6400 graft DHI hair transplant in Turkey, combined with scalp micropigmentation (SMP), to address severe hair loss from Norwood 7. He uses finasteride, oral and topical minoxidil, and GHK-CU, and is satisfied with the results, noting improved hair coverage and confidence despite some remaining thin areas.

A 34-year-old woman has been using a topical solution of 5% Minoxidil and 0.1% Finasteride since January 2026 to address hair thinning caused by PCOS and poor nutrition. She reports ongoing hair shedding but has improved her diet with whole foods and supplements.

An arthritis drug restored significant hair in people with alopecia areata, but it is not effective for male pattern baldness. The drug, Upadacitinib, has serious side effects and is expensive.

A user reported visible hair regrowth after using finasteride for almost six months and inquired if results continue improving over time. They also mentioned using finasteride with sulforaphane and experiencing only minor side effects initially.

The user visited a dermatologist for hair loss and was prescribed finasteride and minoxidil tablets, along with a caffeine hair serum. They decided against painful and costly treatments like PRP and exosome therapy, opting instead to stick with medications and possibly accept going bald.

A user shared their positive experience and results 10 months after a hair transplant at Mercure Istanbul Clinics, using 3000 grafts. They expressed satisfaction with both the outcome and the clinic's service.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.

Exosome therapy showed promising results for burn recovery but was less effective for hair loss. The conversation highlights skepticism about the visible results due to makeup and discusses the complexity of treating hair compared to skin.

The user experienced hair regrowth after starting finasteride in September 2025 and topical minoxidil in December 2025, despite setbacks from using tretinoin gel. Their current treatment includes dutasteride, finasteride, topical minoxidil, and dermastamping.

The user is undergoing treatment for hair loss using finasteride, Kenalog injections, and Clobetasol, along with vitamin D and collagen supplements. They are considering additional treatments like minoxidil and microneedling, and there is discussion about whether the hair loss is due to stress, alopecia areata, or a scarring condition like lichen planopilaris.

BPC-157 is debated for hair loss, with some claiming it helps, but most agree there's no solid evidence for hair regrowth. Finasteride is mentioned as a common treatment, but results vary.

Hair fibers effectively cover thin hair areas, boosting confidence and reducing stress about hair appearance. Users discuss combining hair fibers with other products like hair spray, dermmatch, and Boldify, noting challenges like blocking minoxidil absorption and the importance of color matching.

The conversation is about finding providers for Dutasteride Mesotherapy in the US, which is more common in Europe. The user is asking if any mesotherapy/PRP clinic could offer it if they provide the Dutasteride.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A user shared their positive experience with a hair transplant of 2450 grafts, noting improved hairline and density while continuing minoxidil and finasteride. The procedure cost Rs 90000, and others complimented the results.

The conversation is about recommending a biotin supplement that includes saw palmetto and possibly copper for hair loss. The user is seeking suggestions for these specific ingredients.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Alfatradiol is used by some for hair loss, often alongside treatments like finasteride, RU58841, and minoxidil, but its effectiveness is unclear. Some users report no significant improvement, while others note reduced sebum production but experience side effects like gallbladder pain.

Twist-1 is being explored as a promising early-stage hair loss treatment, while Scube-3's effect on Twist-1 in breast cancer cells raises concerns about its use for hair loss. The conversation discusses the potential differences in protein effects across various cell types.